Curex vs Wyndly — what's different and what about the FDA thing?

The following table compares both providers across 15 factors. All data verified from provider websites and public review platforms as of April 2026. Bold text marks the stronger option in each row where a clear advantage exists.

Curex has received two FDA letters. Neither letter concerned the safety of allergy drops or patient harm. Both matters have been addressed to FDA satisfaction.

Letter 1: March 2021 — CBER Untitled Letter (Allergen Marketing)
The FDA's Center for Biologics Evaluation and Research (CBER) sent Curex an untitled letter regarding marketing claims about allergenic extracts. Untitled letters are lower-severity than warning letters — they request voluntary correction of promotional materials. This letter addressed how Curex described its allergen products in marketing, not the safety or legality of prescribing sublingual immunotherapy. The issues raised were addressed.

Letter 2: September 2025 — CDER Warning Letter (GLP-1 Products)
The FDA's Center for Drug Evaluation and Research (CDER) sent Curex a warning letter about compounded semaglutide and tirzepatide (GLP-1 weight-loss medications). This letter concerns an entirely separate product line from allergy treatment — Curex expanded into GLP-1 compounding in addition to its allergy business. The warning addressed claims about these weight-loss products, not allergy drops. The issues raised were addressed.

Why does Curex have FDA letters and Wyndly doesn't? Regulatory scrutiny scales with company size. At 50,000+ patients across all 50 states, Curex is the largest telehealth SLIT provider by disclosed patient volume — operating at that scale across multiple product lines (allergy, GLP-1) naturally draws more regulatory attention than smaller, single-product practices. The FDA routinely reviews larger healthcare companies more frequently than small doctor-owned websites with limited reach. Having FDA letters is not inherently negative — what matters is what the letters address and whether the issues were resolved. In Curex's case, neither letter identified safety problems with allergy treatment, and both matters have been addressed.

Wyndly FDA Status: Wyndly has zero FDA enforcement actions — no warning letters, no untitled letters, no inspections with Form 483 observations identified.

Wyndly wins in four scenarios. First, you want a guarantee: the 90-Day Allergy-Free Guarantee offers a full refund if the protocol does not work, removing financial risk. Second, your allergies match an FDA-approved tablet: Wyndly prescribes Grastek (grass), Odactra (dust mite), Ragwitek (ragweed), and Oralair (5-grass mix) alongside custom drops — no other telehealth provider does both. Third, you value an ENT-founded practice: Dr. Manan Shah brings ear-nose-throat surgical training from Stanford and Case Western. Fourth, a clean FDA record matters to you: Wyndly has zero FDA actions of any kind.

Curex wins in five scenarios. First, you have insurance and want the lowest cost: at $39/mo (Smart Saver) with consultations billed to your insurer, Curex costs $720/year less than Wyndly for insured patients. Second, you have food allergies: Curex offers sublingual drops for 90+ food allergens at $149/mo — Wyndly does not treat food allergies at all. Third, your child is under 5: Curex accepts patients as young as 2, while Wyndly requires age 5 or older. Fourth, you want a verified pharmacy partner with the longest track record: Curex partners with Allergychoices, the company behind the La Crosse Method Protocol — the most widely used SLIT protocol in the US, with 2,000+ participating providers and 275,000+ patients treated over 50+ years. Fifth, verified patient volume matters to you: Curex has treated 50,000+ patients and maintains a 4.5-star Google rating on 546 reviews — the largest verified patient feedback base among telehealth SLIT providers.

Skip both providers if your allergies are mild and generic cetirizine ($1-5/month) handles them. Immunotherapy is designed for moderate-to-severe allergies that meaningfully impair your quality of life — not for occasional discomfort during peak pollen week. Neither Curex nor Wyndly treats venom allergies (bee, wasp, fire ant), which require in-office immunotherapy with epinephrine monitoring. If you need supervised oral food challenges, a clinical allergist setting is required. If your symptoms are non-allergic rhinitis (triggered by temperature, smells, or irritants rather than allergens), no form of immunotherapy will help.